Healthcare payers around the world face the “perfect storm” of unsustainable budget deficits, aging populations, growing demand for high-quality healthcare services, and burgeoning drug pipelines. To have any hope of controlling their pharmaceutical spending, payers need to find new ways to manage market access.The use of value-based pricing (VBP)—setting drug prices based on willingness to pay or the perceived level of additional benefit—is increasingly common. The burden of meeting payers’ health technology assessment (HTA) requirements is set to increase steadily, as more and more countries adopt this practice. Many payers are also making use of external reference pricing—benchmarking the proposed price for a new drug against its price in comparator countries. Managed entry arrangements can offer a way to overcome barriers to market access at launch, but manufacturers need to understand how countries differ in their approaches to managed entry.
Markets covered: Argentina, Australia, Belgium, Brazil, Canada, China, Colombia, Egypt, France, Germany, India, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, United Kingdom.